Àrgentil invests in Sygen Pharmaceuticals

19 Jan 2021

Àrgentil Capital Management Limited (“Àrgentil”) is pleased to announce its equity investment in Sygen Pharmaceuticals Limited (“Sygen”). The investment was structured via the sponsors’ investment vehicle, Consumer Growth Partners along with other co-investors.

Sygen is an indigenous pharmaceutical company incorporated in 2019 to acquire the key operating assets of Nigerian German Chemicals (NGC). Prior to its acquisition NGC remained a well-known brand in Nigeria with operations spanning over 50 years.

Sygen produces and distributes pharmaceuticals products covering Analgesic, Anti-Diabetics, Antifungal, Anti-spasmodic, Cough medications and Hematinic drugs segments under the NGC brand name. The company also manufactures beverage and bottled water. The Company operates a factory in Ogun state, south west Nigeria and eight depots across the country.

Sygen’s vision is to build a leading pharmaceutical business focused on manufacturing and distributing affordable quality drugs that are readily available and easily accessible to the middle and lower-income demographic of the economy. 

Àrgentil invested in the transaction based on the management teams strong track record in excess of 155 years’ leading and managing operations of FMCG companies in Nigeria and other emerging markets. The healthcare and consumer sector continue to provide significant growth opportunities to companies like Sygen who can deliver quality affordable drugs to a large domestic market.

Àrgentil currently invests in SMEs via the Àrgentil Principal Investment Portfolio II (APIP II) which has completed five investments to date. APIP II's investments have received award recognition including the Private Equity Africa 2019 Deal of the Year (Small Cap) award and many of our investee companies are making significant positive impact in the current COVID-19 environment. Àrgentil is also expanding its investment focus via the US$95m Àrgentil SME Investment Fund (ASIF) to cover key West Africa countries.

ASIF will invest in key growth sectors including Agribusiness, Consumer, Technology and Energy. ASIF’s initial country focus will cover Ghana, Liberia, Nigeria and Sierra Leone. Àrgentil also makes direct investments from its balance sheet to support management teams or sponsor new businesses that seek to create platforms that can scale over time to execute growth strategies in key sectors. To date Àrgentil has made directs investments in the consumer / healthcare and clean energy space.

Gbenga Hassan, partner at Àrgentil led the deal.

« Back to Member News

Isabelle Bébéar is the Director of International & European Affairs at @Bpifrance. We caught up with her to discuss… https://t.co/nkVqrB8zX1

RT @forbesafrica: Of all the sectors, the world of private equity gets the most rap for its exclusive male-dominated culture. @Abi_Mustapha…

Are you fundraising or thinking of fundraising this year? Sign up for the Fund Manager Pitch Clinic at #AVCA2021 an… https://t.co/JFjcfut7bg

RT @AMIC_PE_morocco: Join the @AVCA_Africa for a virtual experience on best practices for fundraising and fund structuring, investors succe…

Together with our colleagues at EAVCA, SAVCA and PEVCA, we are delighted to join forces with FSD Africa to support… https://t.co/ThQq4Ns6RP

;